Nat. Volatiles & Essent. Oils, 2021; 8(6): 6295-6309

NVEO
Natural Volatiles &
Essential Oils

An Investigation On The Antiviral Activity, Pharmacokinetic Properties, And Therapeutic Efficiency Of Hiv Infection Treatment: A Review

MD. ANAS QAMAR , Mrs. CHANDA RAY , Mrs. SANDHYA SHARMA

Department of Pharmaceutics, Innovative College of Pharmacy, Knowledge Park II, Greater Noida, Uttar Pradesh, 201308.

Abstract

Antiviral pharmaceuticals are drugs that have been approved by the Food and Drug Administration (FDA) to treat or manage viral infections. Antiviral medications can also be used to prevent viral infections. The majority of antiviral drugs that are currently available on the market are designed to target distinct stages of the life cycle of viruses. Scientists are interested in a number of different stages of the life cycle of viruses, including viral attachment to a host cell, uncoating, viral RNA and DNA synthesis, viral RNA and DNA replication, viral protein maturation, budding, viral protein release, and viral protein release in bodily fluids. At this time, at least half of the antiviral medications that are currently available are being used to treat HIV infections. These drugs can also be used to treat a wide range of other viruses, such as herpes, hepatitis B and hepatitis C, as well as respiratory viruses. A variety of nonspecific phagocytic and cytolytic leukocytes, in addition to cytokines such as antivirally active interferons, are all examples of mammalian innate immune defences that are covered in this work. Innate immune defences are also a topic of discussion. Because IFNs and the antiviral factors that are produced as a result of IFNs are our primary lines of defence against viral infections, interferon-mediated activation of IFN transcription, IFN signalling, and the production of antiviral factors are all of great interest.

Introduction

Antiviral pharmaceuticals are drugs that have been evaluated and given approval by the FDA for the treatment or prevention of viral infections. Any antiviral treatment that interacts, even slightly, with components of the host cell has the potential to be harmful to the host, depending on how long the treatment is taken for and how much of it is taken[1]. This is because of the delicate relationship that exists between viral replication and the host cell. At the moment, there are only a select few antiviral medications available for use [2-4]. The steps of the viral life cycle that are targeted include attachment to the host cell, uncoating, viral mRNA synthesis, viral mRNA translation, viral RNA and DNA replication, generation of new viral proteins, budding, release of newly made virus, and free virus in body fluids. The number of antiviral drugs that can be used to treat viral diseases at this time is highly limited, and at least half of these compounds are used to treat infections caused by HIV[5]. The herpes simplex virus (HSV), the varicella-zoster virus (VZV), the influenza virus, cytomegalovirus (CMV), the hepatitis B virus

(HBV), and the hepatitis C virus are some of the illnesses that can be treated with other antiviral medications (HCV).

It is possible for viruses to persist in cells in one of two ways: either as episomal forms or by getting integrated into the chromosomal DNA of the host (i.e., viral latency state)[6]. The actively replicating viruses as well as the dormant viruses are the perfect targets for an ideal antiviral drug. However, the great majority of antiviral treatments that are currently available only operate against replicating viruses. When treating an immunocompetent patient for an acute virus-related illness, the primary focus of treatment should be on lowering the likelihood of disease complications while also lowering the likelihood of virus transmission [7-9]. The therapeutic index, which evaluates the efficacy of a treatment in relation to the risks associated with it, must be exceptionally high for a treatment to be approved for use. Only then can a treatment be deemed appropriate. When there is a prolonged viral infection, it is essential to prevent damage to the visceral organs caused by the virus; consequently, effectiveness is essential. Antiviral medications have a variety of potential applications, including illness treatment, prevention, reduction of viral activity, and even preemptive therapy. Toxicities caused by antiviral drugs, as well as the virus's ability to build resistance to antiviral drugs, can limit the efficiency of antiviral drugs[10]. Variables that can be found in a person's genome or epigenome, as well as the host's phenotypic responses to antiviral medications, can all have a role in limiting the effectiveness of antiviral treatments. This article will describe the pharmacologic and clinical characteristics of antiviral medications that are now available on the market that are considered to be the most important.

Mechanism of Action

Since the beginning of human civilization, infectious diseases such as viruses and other pathogens have been present. Infectious diseases are caused by a wide variety of bacteria, viruses, and parasites (bacteria, viruses and fungi). In contrast to the convoluted structures of fungi, helminths, and protozoa, viruses are characterised by a straightforward protein coat and nucleic acid nucleotide sequences[11]. As a result of the fact that they proliferate via the host cell's machinery, viruses are also considered to be obligatory intracellular pathogens. Because of these qualities, it is challenging to develop treatments that have a toxicity that is particular to viruses. Viruses, which are extremely minute creatures containing genetic material that can be made of either DNA or RNA, are the cause of a wide variety of diseases that can affect not just people but also animals and plants[12]. People and viruses are engaged in a conflict that will never be resolved since both sides will employ a variety of strategies to combat the other. The development of antiviral drugs entails a number of stages, including target discovery and screening, lead generation and optimization, clinical investigations, and the registration of the drug, amongst others. Because viral illnesses have been responsible for the deaths of millions of people throughout the course of human history, the development of novel antiviral medications is an urgent imperative. Idoxuridine was the first antiviral medicine to be licenced by the Food and Drug Administration (FDA) in June 1963[13]. This event marked the beginning of a new era in the study of antiviral drugs. As a direct consequence of this, a wide range of antiviral medicines have been developed and made available for the treatment of millions of patients all over the world. In the treatment of viral infections, the use of antiviral medication is an extremely widespread and standard practice [14-16]. Certain

antiviral drugs, similar to antibiotics for treating bacteria, are utilised in the treatment of specific viruses. Antiviral drugs do not typically cause the death of their targets, in contrast to antibiotics. Instead, they stunt the increase of the population. Because viruses can only replicate within the cells of their host, it can be difficult to develop antiviral medications that are both safe and effective[17]. Therefore, it is difficult to discover therapeutic targets that could interfere with the virus without also causing damage to the host cells. In addition, the diversity of viruses makes the research and development of antiviral medications and vaccines far more challenging. In the 1990s, for instance, computer-based drug discovery was a crucial tool for discovering antiviral drugs, and it was through this process that nelfinavir was found to be an effective treatment for HIV infection [18-20].

Despite the utilisation of cutting-edge technology and stringent quality control procedures, only a select few antiviral medications have been granted approval for use in humans. This is either because of the potential for adverse effects or because viruses have become resistant to antiviral therapies. As our knowledge of viruses, their infection mechanisms, and the rapidly developing antiviral technologies and procedures grows, the rate at which new antiviral treatments are developed will quicken[21]. This is because of the positive feedback loop that results from these developments. It would appear that new microbiological dangers will continue to emerge at an ever-increasing rate, mostly due to the fact that climate change and globalisation are both occurring at an increasingly rapid rate[22].

DNA virus

The single-stranded DNA is what is left over after a virus with a double strand of DNA, such as an adenovirus, herpes virus, or papilloma virus, has replicated. After entering a cell, DNA viruses are able to proliferate and then move on to infect additional cells.

RNA virus

All of these viruses are referred to as RNA, and they include the common cold, measles, mumps (colds), meningitis (polio), retroviruses (AIDS and T-cell leukaemia), and arena viruses. RNA viruses cause infectious diseases (ssRNA). There is no way for an RNA virus to get inside the nucleus of the cell (in addition to the cold virus contamination this season). After the viral RNA has been converted into a DNA copy, the information is first organised by the genome of the host, and then it is passed on through retroviruses [23-25].



Fig: 1 Common Inhibitor action of Antiviral drugs[26]

When viruses attempt to invade mammalian bodies, they face a formidable challenge in the shape of an obstacle course. The word "innate immunity" now refers to everything that can prevent, stop, or slow down the spread of diseases in a rapid and non-specific manner while also not establishing a long-lasting protective memory [27-30]. This meaning of "innate immunity" is intended to be more inclusive than the previous one. It is general knowledge that many of these defence mechanisms, which are highly effective and in no way primitive, can be found in metazoans of all types. However, in the sake of brevity, the majority of this article will be devoted to mammals.

Antiviral Innate Immunity

It is possible to classify the various components of the mammalian innate immune system that protect against virus infections into a great deal of different subgroups. Some of these subgroups include mechanical and chemical barriers, defensins, complement, phagocytic/cytolytic cells, and cytokines. In addition, it is possible to classify these subgroups separately from one another. The macrophages/monocytes, granulocytes, neutrophils, natural killer cells, and dendritic cells that make up the cellular branch of the innate immune system are what make up the innate immune system. Monocytes travel through the circulatory system for a number of hours before differentiating into macrophages [31]. In either scenario, these potent phagocytic cells are able to swiftly clear specific tissues of virus particles as well as apoptotic bodies (such as the Kupffer cells of the liver). In addition, activated macrophages have the ability to produce inflammatory cytokines such as interferon (IFN-) and tumour necrosis factor. These cytokines are produced by activated macrophages (TNF-). Phagocytosis is an

additional method that granulocytes use to remove viral particles and bodies that have undergone apoptosis. After being rapidly drawn to inflammatory sites, they enter the tissue through a process called transendothelial migration. This is the way by which they invade the tissue [32]. The viral proteins that are swallowed are broken into fragments by macrophages and granulocytes, and these fragments are subsequently presented to T cells for immune response. Another direct function carried out by neutrophils is the phagocytosis of infectious agents (polymorphnuclear cells). The most intriguing capability of neutrophils is known as neutrophil extracellular traps (NETs), which are networks made up of proteins and chromatin that trap and destroy extracellular pathogens. Natural killer (NK) cells have the ability to recognise and eliminate infectious cells on their own, without the assistance of antigens. These cells' quick production of enormous amounts of IFN- causes an activation of the adaptive immune system. This activation is caused by the activation of the immune system's memory [33-36]. The receptors that either excite or inhibit natural killer (NK) cells are delicately balanced. The ability to destroy cells that do not have MHC I molecules on their surface is one of their most prominent characteristics since it allows them to do so. Because many viruses downregulate MHC expression in order to evade an adaptive immune response, NK surveillance is an essential early warning and assault mechanism against virus infections. This is because NKs are able to directly target and destroy infected viruses. Dendritic cells play an essential role in connecting the innate immune system with the adaptive immune system (DCs). These specialised immune cells collect antigen at the site of an infection, produce cytokines, and then go to lymphatic organs that are secondary to the lymphatic system [37-40]. This is done in order to activate T cells so that they can fight against the antigen. In order to convert DCs into antigen-presenting cells (APCs), cytokine synthesis needs to be triggered by pathogen-specific molecular patterns, which then causes production of cytokines (PAMPs). Myeloid DCs and plasmacytoid DCs are the two basic subtypes that may be distinguished from one another using DCs (pDCs). They originate from myeloid bone marrow progenitors, which are the same cells that, amongst other things, are responsible for the differentiation of macrophages/monocytes and granulocytes. Langerhans cells, which are found in the epidermis and epithelia, and interstitial cells, which are found in the interstitial space, are two examples of mDC subsets. Interstitial cells dwell in the gap between connective tissues [41-44]. pDCs originate from lymphatic precursor cells, which also give rise to B and T cells. pDCs do not have distinct subpopulations since they do not differentiate. Both myeloid and polymorphonuclear dendritic cells (mDCs and pDCs) are equipped with a wide array of PAMP receptors, which allow them to detect viral infections both inside and outside the cell. Depending on the kind of DC, large quantities of interleukins or interferons (IFNs) are being produced, which in turn initiates the ensuing immune response. pDCs are responsible for the potent production of type I IFNs.

Anti-viral for Covid-19

As a direct consequence of the ongoing pandemic of coronavirus disease 2019 (COVID-19), which is believed to be caused by the severe acute respiratory syndrome coronavirus type 2, humanity is currently confronted with a myriad of difficulties (SARS-CoV-2). 1 and 2 By the end of July 2020, there were over 12 million confirmed instances of COVID-19, which resulted in over a half a million fatalities. 3 Headaches, dizziness, and abdominal pain are less common COVID-19 symptoms than fever, dry cough,

dyspnea, chest pain, tiredness, and myalgia. Fever, dry cough, and dyspnea are the most common COVID-19 symptoms. Infections caused by SARS-CoV-2 normally cause no symptoms or only modest clinical signs; nonetheless, the healthcare system is being overburdened as a result of the high number of patients who need to be hospitalised to the intensive care unit (ICU)[45]. 5 There is a possibility that a disruption in the host immune response contributes to the severity of the disease. 6 SARS-CoV-2 has a bigger basic reproduction number (R0) than SARS Coronavirus, which accounts for its higher fatality rate, which can reach up to 6.2 percent as of April 13, 2020. (SARS-CoV). The families Coronaviruses and Coronavirinae, as well as the subfamily Coronavirinae, the genus Betacoronavirus, the SARS-CoV-2 coronavirus, and the Middle East Respiratory Syndrome coronavirus are all members of the genus Betacoronavirus (MERS-CoV). The enveloped particle (E) of the CoV-2 virus contains a positive-stranded RNA particle (Psp) that binds to the nucleocapsid (N) contained within the membrane protein (M) of the virus (S). The receptor angiotensin-converting enzyme 2 in cells is required for viral entry into host cells, and the RBD domain of the S protein is needed for this [46]. S protein (ACE2). It should come as no surprise that SARS-CoV-2 harnesses the machinery of the host cell to proliferate and spread because this is something that other viruses have done in the past.

There is currently no licenced medication for the treatment of COVID-19, nor is there a medication that has been specifically designed to treat SARS-CoV-2. During this period of crisis, it is imperative that existing antiviral treatments for patients with COVID-19 be rapidly reviewed, and that novel antivirals be developed as quickly as humanly possible [48]. Antiviral drugs have to target the viral replication cycle at any one of these crucial stages in order to stop the virus from taking over the host system and using it for its own purposes (uncoating, reverse transcription, transcription, translation, and release of the virion). More than eighty different antiviral drugs are currently on the market and have been licenced for use in the treatment of viral infections in humans. The majority of these drugs are utilised in the treatment of HIV infection, whereas the remaining drugs are utilised in the treatment of herpes simplex virus, influenza A and B, Ebola virus, cytomegalovirus (CMV), hepatitis A and C virus (HAV and HCV), and Ebola virus (HSV). During the current COVID-19 pandemic, certain antivirals have been used to treat patients who have contracted the virus in certain countries. Antivirals against COVID-19 are currently being investigated in clinical trials all around the world; consequently, the types of antivirals currently in use are very diverse.

Acyclovir



Infections caused by the herpes simplex virus are responsive to treatment with acyclovir (HSV). The Food and Drug Administration has given its blessing for its use in the treatment of genital herpes and HSV encephalitis[49]. At the present moment, the Food and Drug Administration has not approved any indications for the treatment of herpes simplex virus (HSV), shingles, or varicella-zoster (chickenpox). Acyclovir is the medicine of choice for treating HSV encephalitis as a first-line therapy. There is currently no alternative drug that has been shown to be successful in treating this condition, and this is likely to remain the case for the foreseeable future.

Since HSV encephalitis has been treated with acyclovir for such a long time, there has been no comprehensive investigation of the effectiveness of the disease in conjunction with the medication. The rate of deaths is the most important endpoint that is considered in modern systematic studies that investigate the drug's safety and effectiveness. The measurement of one's quality of life is an additional outcome metric[50].

Oral acyclovir and topical steroids have both been shown to be beneficial in the treatment of HSV keratitis in paediatric patients. When treating eczema herpeticum in HIV patients, acyclovir is occasionally utilised as a treatment option. By using it, one can avoid getting infections of the skin, as well as of the eyes, nose, and mouth. Eczema herpeticum is a very uncommon disorder; but, if it is allowed to progress unchecked, it can become significantly more severe and can be fatal[51-53]. The treatment with intravenous acyclovir should be given to patients who have substantial involvement, systemic symptoms, or decreased oral intake. Acyclovir is an additional potential treatment option for oral hairy leukoplakia.

A myelopathy that is brought on by an infection with varicella-zoster can be treated with acyclovir. In a small case series that was examined from 1994 to 2014, the majority of patients who had laboratory-confirmed VZV and MRI-confirmed myelopathy saw a significant improvement in their symptoms within two months. This improvement occurred in patients who were analysed between 1994 and 2014.

It has been demonstrated that the antiviral medication acyclovir is useful in the treatment of visceral diffused VZV infection as well as brachial plexus neuritis (characterised by abdomen and absence of skin lesions).

When administered to patients who have had hematopoietic stem cell transplantation, acyclovir has the potential to prevent infections caused by the herpes simplex virus as well as varicella-zoster. Prophylaxis with acyclovir should also be considered for organ recipients who are seropositive for both HSV-1 and HSV-2. Because of what we did, the number of people becoming sick from viruses has gone down. It is possible that a problem could be caused by an infection that spreads swiftly. People who have discontinued their use of acyclovir as a preventative measure are at an increased risk of contracting HSV and VZV.

Acyclovir is another medication that is recommended for use as a prophylactic treatment for a variety of conditions. One of these conditions is juvenile-onset recurrent respiratory papillomatosis. In a study that was conducted using a prospective observational method and involved 21 patients, oral acyclovir was utilised as a postoperative adjuvant[54]. It has been proved to lessen the occurrence of papilloma, which in turn reduces the necessity for later operations and the risks connected with them.

One of the many adverse effects that can be brought on by infections brought on by VZV is a condition known as cerebellitis. It has been established that treating an infection at its source lowers the likelihood of developing problems. For instance, a patient diagnosed with truncal ataxia was discussed in a case report published in 2019. After receiving therapy with intravenous acyclovir, the patient no longer exhibited any signs of impairment or cerebellitis. Oral acyclovir has been shown to be effective in treating herpes zoster-induced paresis. This type of paresis develops when the herpes zoster virus affects motor nerve fibres in addition to or instead of the dorsal root ganglia.

Mechanism of Action

An antiviral medication known as acyclovir binds to viral DNA and stops it from being synthesised in the body, hence preventing the spread of infectious viruses. When converted by viral and cell enzymes, acyclovir triphosphate blocks the formation of new DNA and prevents the replication of viruses. Acyclovir is a synthetic purine nucleoside analogue that has been demonstrated to decrease the activity of the herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) as well as the varicella-zoster virus.

Valacyclovir

An antiviral medicine called Valacyclovir, which is derived from acyclovir, has been created specifically for the treatment of herpes simplex and varicella-zoster virus infections. There have been a few reports of patients developing modest liver damage that was clinically obvious after taking valacyclovir. Valacyclovir, the active moiety, is quickly converted into valacyclovir, the L-valyl ester prodrug of acyclovir, which is named valacyclovir (val" ay sye' kloe vir). This transformation takes place within the body. Valacyclovir is superior to acyclovir in terms of oral bioavailability, as well as herpes viral activity, such as herpes simplex 1 and 2 and CMV. This is also the case when comparing the two drugs in terms of herpes viral activity. After it has been changed into acyclovir, viral kinases will phosphorylate the acyclovir that is found inside the cell. The integration of the triphosphate into viral DNA is hindered

because guanosine acts as a competitor to the triphosphate and inhibits viral DNA polymerase[55-57]. Because viral kinases are necessary for the activation of valacyclovir, this antiviral medication can only work in cells that have been infected by viruses. With the assistance of valacyclovir, it is possible to treat mucocutaneous and genital herpes simplex type 1 and 2 in addition to herpes zoster. Valacyclovir is also effective in treating herpes zoster. In the United States, the treatment and prevention of genital and mucocutaneous herpes simplex infection with valacyclovir has been regularly used since the year 1995. Valacyclovir is sold both generically and under the brand name Valtrex in the form of capsules containing either 500 or 1000 milligrammes. It is common practise to recommend that adults take between 500 and 1000 mg per day, either once or twice, in divided doses. Aches and pains in the stomach, as well as headaches and dizziness, are among the most common adverse reactions. Renal failure, affects on the central nervous system, and severe thrombocytopenia are all side effects that can occur, but they are quite serious when they do.

Mechanism of Action

Valacyclovir can be used as a starting material for the production of acyclovir, which is the active component of acyclovir triphosphate (ACV-TP). ACV-TP is an antiviral drug that works by competing with viral DNA polymerase, inhibiting viral DNA polymerase, and ultimately terminating and inactivating viral DNA polymerase.

Famiciclovir

A medicine known as famciclovir is used to treat infections caused by herpes as well as varicella-zoster. Nucleoside analogues are a type of antiviral drug that works by mimicking the effects of nucleosides. In this activity, the indications, action, and contraindications of the medicine famciclovir are explained. Famciclovir is a beneficial drug for treating herpes and varicella-zoster infections, and the activity focuses on these topics [58]. Treatment for herpes and varicella-zoster infections, as well as illnesses associated with them, requires a comprehensive understanding of how the medications work, as well as the types of side effects they can cause. This includes both the potential for the medications to cause adverse reactions and the potential for the medications to cause beneficial reactions.

Mechanism of action

Penciclovir is the active antiviral ingredient of famciclovir, which is initially transformed into penciclovir. Penciclovir is then administered to patients. The viral thymidine kinase (TK) that can be seen in cells infected with HSV-1, HSV-2, and varicella-zoster virus converts penciclovir to monophosphate after being phosphorylated. Penciclovir is incapable of being phosphorylated by healthy cells; as a result, it can only harm infected cells [59-60]. In the subsequent phase, the enzymes found in the host cell convert penciclovir monophosphate into the penciclovir triphosphate form. Competition between penciclovir triphosphate and deoxyguanosine triphosphate, which results in inhibition of herpes virus DNA polymerase and chain termination, which ultimately results in the death of viral replication, is caused by penciclovir triphosphate.

Conclusion

Both humans and viruses are waging a battle of attrition against one another, and both sides are always improving their strategies. Over the past few decades, there has been significant advancement in our understanding of the genetic and molecular pathways that underlie disease. There have been a number of recent advances in medical treatment, and many more are still in the research and development stage. There is still a serious threat posed by COVID-19 and other newly developing infectious diseases, such as those caused by viruses similar to this one. The ineffectiveness of drugs un clinical trials involving humans is a widespread problem that needs to be researched and resolved. As more and more cutting-edge technology become available, it is anticipated that the results will be quite promising. The ever-expanding collection of knowledge about viruses and the lightning-fast evolution of techniques and instruments are both useful in the search for new antiviral drugs. Because of the growing understanding of viruses and the efforts of researchers all around the world, we have high hopes that one day we may be able to live in a world where viral infections no longer exist.

References

1. Antinori A, Zaccarelli M, Cingolani A, Forbici F, Rizzo MG, Trotta MP, Di Giambenedetto S, Narciso P, Ammassari A, Girardi E, et al. 2002. Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure. AIDS Res Hum Retroviruses 18: 835–838

2. Kumar, R., Saha, P., Kumar, Y., Sahana, S., Dubey, A., & Prakash, O. (2020). A Review on Diabetes Mellitus: Type1 & Type2. World Journal of Pharmacy and Pharmaceutical Sciences, 9(10), 838-850.

3. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, Katlama C, Debre P, Leibowitch J 1997. Positive effects of combined antiretroviral therapy on CD^{4+} T cell homeostasis and function in advanced HIV disease. Science 277: 112–116

4. Baba M, Miyake H, Wang X, Okamoto M, Takashima K 2007. Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652. Antimicrob Agents Chemother 51: 707–715

5. Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Baruch A, Jones M, Facey K, Whitacre C, McAuliffe VJ, et al. 1996. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med 334: 1011–1017

6. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quintero JC, Rhodes A, Robbins HL, Roth E, Shivaprakash M 1995. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature (London) 374: 569–571

7. Daharia, A., Jaiswal, V. K., Royal, K. P., Sharma, H., Joginath, A. K., Kumar, R., & Saha, P. (2022). A Comparative review on ginger and garlic with their pharmacological Action. Asian Journal of Pharmaceutical Research and Development, 10(3), 65-69.

8. St Clair MH, Richards CA, Spector T, Weinhold KJ, Miller WH, Langlois AJ, Furman PA 1987. 3'-Azido-3'-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase. Antimicrob Agents Chemother 31: 1972–1977

9. KUMAR, A. (2019). The Scenario of Pharmaceuticals and Development of Microwave Assisted Extraction Techniques.

10. Kumar, R., Saha, P., Lokare, P., Datta, K., Selvakumar, P., & Chourasia, A. (2022). A Systemic Review of Ocimum sanctum (Tulsi): Morphological Characteristics, Phytoconstituents and Therapeutic Applications. International Journal for Research in Applied Sciences and Biotechnology, 9(2), 221-226.

11. Wiersinga WJ, Rhodes A, Cheng AC, et al.. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324:782–793.

12. Nyarko, R. O., Kumar, R., Sharma, S., Chourasia, A., Roy, A., & Saha, P. (2022). ANTIBACTERIAL ACTIVITY OF HERBAL PLANT-TINOSPORA CORDIFOLIA AND CATHARNTHUS ROSEUS.

13. Saha, P., Nyarko, R. O., Lokare, P., Kahwa, I., Boateng, P. O., & Asum, C. (2022). Effect of Covid-19 in Management of Lung Cancer Disease: A Review. Asian Journal of Pharmaceutical Research and Development, 10(3), 58-64.

14. Bind, A., Das, S., Singh, V. D., Kumar, R., Chourasia, A., & Saha, P. Natural Bioactives For The Potential Management Of Gastric Ulceration. Turkish Journal of Physiotherapy and Rehabilitation, 32(3).

15. Wainberg MA, Miller MD, Quan Y, Salomon H, Mulato AS, Lamy PD, Margot NA, Anton KE, Cherrington JM 1999. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antiviral Therapy 4: 87–94

16. Kumar, R., Saha, P., Pathak, P., Mukherjee, R., Kumar, A., & Arya, R. K. EVOLUTION OF TOLBUTAMIDE IN THE TREATMENT OF DIABETES MELLITUS. Jour. of Med. P'ceutical & Alli. Sci, 9.

17. Saha, P., Kumar, R., Nyarko, R. O., Kahwa, I., & Owusu, P. (2021). HERBAL SECONDARY METABOLITE FOR GASTRO-PROTECTIVE ULCER ACTIVITY WITH API STRUCTURES.

18. Kumar, R., Jain, A., Tripathi, A. K., & Tyagi, S. (2021, January). Covid-19 outbreak: An epidemic analysis using time series prediction model. In 2021 11th international conference on cloud computing, data science & engineering (Confluence) (pp. 1090-1094). IEEE.

19. Nyarko, R. O., Saha, P., Kumar, R., Kahwa, I., Boateng, E. A., Boateng, P. O., ... & Bertram, A. (2021). Role of Cytokines and Vaccines in Break through COVID 19 Infections. Journal of Pharmaceutical Research International, 33, 2544-2549.

20. Zennou V, Mammano F, Paulous S, Mathez D, Clavel F 1998. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J Virol 72: 3300–3306

21. PURABISAHA, R. K., RAWAT, S. S. N., & PRAKASH, A. (2021). A REVIEW ON NOVEL DRUG DELIVERY SYSTEM.

22. Nyarko, R. O., Boateng, E., Kahwa, I., Boateng, P. O., & Asare, B. (2020). The impact on public health and economy using lockdown as a tool against COVID-19 pandemic in Africa: a perspective. J Epidemiol Public Health Rev, 5(3).

23. Veazey RS, Klasse PJ, Ketas TJ, Reeves JD, Piatak M Jr, Kunstman K, Kuhmann SE, Marx PA, Lifson JD, Dufour J, et al. 2003. Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection. J Exp Med 198: 1551–1562

24. Raj, A., Tyagi, S., Kumar, R., Dubey, A., & Hourasia, A. C. (2021). Effect of isoproterenol and thyroxine in herbal drug used as cardiac hypertrophy. Journal of Cardiovascular Disease Research, 204-217.

25. Daharia, A., Jaiswal, V. K., Royal, K. P., Sharma, H., Joginath, A. K., Kumar, R., & Saha, P. (2022). A Comparative review on ginger and garlic with their pharmacological Action. Asian Journal of Pharmaceutical Research and Development, 10(3), 65-69.

26. Sahana, S., Kumar, R., Nag, S., Paul, R., Chatterjee, I., & Guha, N. (2020). A REVIEW ON ALZHEIMER DISEASE AND FUTURE PROSPECTS.

27. Nyarko, R. O., Kumar, R., Sharma, S., Chourasia, A., Roy, A., & Saha, P. (2022). ANTIBACTERIAL ACTIVITY OF HERBAL PLANT-TINOSPORA CORDIFOLIA AND CATHARNTHUS ROSEUS.

28. Singh, M. K., Kumar, A., Kumar, R., Kumar, P. S., Selvakumar, P., & Chourasia, A. (2022). Effects of Repeated Deep Frying on Refractive Index and Peroxide Value of Selected Vegetable Oils. International Journal for Research in Applied Sciences and Biotechnology, 9(3), 28-31.

29. Smith PF, Ogundele A, Forrest A, Wilton J, Salzwedel K, Doto J, Allaway GP, Martin DE 2007. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3′,3′-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob Agents Chemother 51: 3574–3581

30. Kumar, R., & Dubey, A. PHYTOCHEMICAL INVESTICATION AND HEPTOPROTECTIVE EVALUTION ACACIA RUBICA EXTRACT ISONIZED AND PARACETAMOL INDUSED ANIMAL TOXICITY. Turkish Journal of Physiotherapy and Rehabilitation, 32(3).

31. Nyarko, R. O., Prakash, A., Kumar, N., Saha, P., & Kumar, R. (2021). Tuberculosis a globalized disease. Asian Journal of Pharmaceutical Research and Development, 9(1), 198-201.

32. Sato M, Motomura T, Aramaki H, Matsuda T, Yamashita M, Ito Y, Kawakami H, Matsuzaki Y, Watanabe W, Yamataka K, et al. 2006. Novel HIV-1 integrase inhibitors derived from quinolone antibiotics.

33. Nyarko, R. O., Boateng, E., Kahwa, I., & Boateng, P. O. (2020). A comparison analysis on remdesivir, favipiravir, hydroxychloroquine, chloroquine and azithromycin in the treatment of corona virus disease 2019 (COVID-19)-A Review. World J. Pharm. Pharm. Sci, 9, 121-133.

34. Sahana, S., Kumar, R., Nag, S., Paul, R., Chatterjee, I., & Guha, N. (2020). A REVIEW ON ALZHEIMER DISEASE AND FUTURE PROSPECTS.

35. Rodgers DW, Gamblin SJ, Harris BA, Ray S, Culp JS, Hellmig B, Woolf DJ, Debouck C, Harrison SC 1995. The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. Proc Natl Acad Sci 92: 1222–1226

36. Sahana, S. (2020). Roshan kumar, Sourav nag, Reshmi paul, Nilayan guha, Indranil Chatterjee. A Review on Alzheimer disease and future prospects. World Journal of Pharmacy and Pharmaceutical science, 9(9), 1276-1285.

37. Saha, P., Kumar, R., Nyarko, R. O., Kahwa, I., & Owusu, P. (2021). HERBAL SECONDARY METABOLITE FOR GASTRO-PROTECTIVE ULCER ACTIVITY WITH API STRUCTURES.

38. Ray PE, Soler-Garcia AA, Xu L, Soderland C, Blumenthal R, Puri A 2005. Fusion of HIV-1 envelope-expressing cells to human glomerular endothelial cells through an CXCR4-mediated mechanism. Pediatr Nephrol 20: 1401–1409

39. Saha, P., Kumar, R., Nyarko, R. O., Kahwa, I., & Owusu, P. (2021). HERBAL SECONDARY METABOLITE FOR GASTRO-PROTECTIVE ULCER ACTIVITY WITH API STRUCTURES.

40. Dubey, A., Yadav, P., Verma, P., & Kumar, R. (2022). Investigation of Proapoptotic Potential of Ipomoea carnea Leaf Extract on Breast Cancer Cell Line. Journal of Drug Delivery and Therapeutics, 12(1), 51-55.

41. Quercia R, Dam E, Perez-Bercoff D, Clavel F 2009. Selective-advantage profile of human immunodeficiency virus type 1 integrase mutants explains in vivo evolution of raltegravir resistance genotypes. Virol J 83: 10245–10249

42. Bind, A., Das, S., Singh, V. D., Kumar, R., Chourasia, A., & Saha, P. Natural Bioactives For The Potential Management Of Gastric Ulceration. Turkish Journal of Physiotherapy and Rehabilitation, 32(3).

43. Kumar, R., Saha, P., Lokare, P., Datta, K., Selvakumar, P., & Chourasia, A. (2022). A Systemic Review of Ocimum sanctum (Tulsi): Morphological Characteristics, Phytoconstituents and Therapeutic Applications. International Journal for Research in Applied Sciences and Biotechnology, 9(2), 221-226.

44. Ray PE, Soler-Garcia AA, Xu L, Soderland C, Blumenthal R, Puri A 2005. Fusion of HIV-1 envelope-expressing cells to human glomerular endothelial cells through an CXCR4-mediated mechanism. Pediatr Nephrol 20: 1401–1409

45. Sahana, S. (2020). Purabi saha, Roshan kumar, Pradipta das, Indranil Chatterjee, Prasit Roy, Sk Abdur Rahamat. A Review of the 2019 Corona virus (COVID-19) World Journal of Pharmacy and Pharmaceutical science, 9(9), 2367-2381.

46. Quan Y, Gu Z, Li X, Li Z, Morrow CD, Wainberg MA 1996. Endogenous reverse transcription assays reveal high-level resistance to the triphosphate of (–)2′-dideoxy-3′-thiacytidine by mutated M184V human immunodeficiency virus type 1. J Virol 70: 5642–5645

47. Kumar, R., Saha, P., Lokare, P., Datta, K., Selvakumar, P., & Chourasia, A. (2022). A Systemic Review of Ocimum sanctum (Tulsi): Morphological Characteristics, Phytoconstituents and Therapeutic Applications. International Journal for Research in Applied Sciences and Biotechnology, 9(2), 221-226.

48. Parikh UM, Bacheler L, Koontz D, Mellors JW 2006. The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. J Virol 80: 4971–4977

49. Roshan, K. (2020). Priya damwani, Shivam kumar, Adarsh suman, Suthar Usha. An overview on health benefits and risk factor associated with coffee. International Journal Research and Analytical Review, 7(2), 237-249.

50. Marinello J, Marchand C, Mott B, Bain A, Thomas CJ, Pommier Y 2008. Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants. Biochemistry 47: 9345–54

51. Umama, Y., Venkatajah, G., Shourabh, R., Kumar, R., Verma, A., Kumar, A., & Gayoor, M. K. (2019). Topic-The scenario of pharmaceuticals and development of microwave as; sisted extraction technique. World J Pharm Pharm Sci, 8(7), 1260-1271.

52. Awuchi, C. G., Amagwula, I. O., Priya, P., Kumar, R., Yezdani, U., & Khan, M. G. (2020). Aflatoxins in foods and feeds: A review on health implications, detection, and control. Bull. Environ. Pharmacol. Life Sci, 9, 149-155.

53. Mansky LM, Temin HM 1995. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 69: 5087–5094

54. SHAFQAT ZAIDI, R. K. MEHRA, Dr. SACHIN TYAGI, ROSHAN KUMAR ANUBHAV DUBEY.(2021). Effect of Kalahari Cactus Extract on Appetitte, Body Weight And Lipid Profile In Cafeteria Diet Induced Obesity In Experimental Animal. Annals of the Romanian Society for Cell Biology, 25(6), 13976-13987.

55. Roshan Kumar, & Purabi Saha. (2022). A Review on Artificial Intelligence and Machine Learning to Improve Cancer Management and Drug Discovery. International Journal for Research in Applied Sciences and Biotechnology, 9(3), 149–156. https://doi.org/10.31033/ijrasb.9.3.26

56. Larder BA, Kemp SD 1989. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246: 1155–1158

57. Li F, Goila-Gaur R, Salzwedel K, Kilgore NR, Reddick M, Matallana C, Castillo A, Zoumplis D, Martin DE, Orenstein JM, et al. 2003. PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Acad Sci 100: 13555–13560

58. Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, Walmsley S, Cohen C, Kuritzkes DR, Eron JJ Jr, et al. 2003. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 348: 2175–2185

59. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA 1992. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256: 1783–1790

60. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, Alldredge L, Hunter E, Lambert D, Bolognesi D, et al. 1998. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 4: 1302–1307